New Share News | Dija Pharmaceuticals (688192.SH) Resubmits Listing Application to Hong Kong Stock Exchange

According to the Hong Kong Stock Exchange's disclosure on August 27, Dize Pharmaceutical Co., Ltd. (referred to as: Dize Pharmaceutical (688192.SH)) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with Goldman Sachs and Huatai International acting as joint sponsors. The company had previously submitted a listing application to the Hong Kong Stock Exchange on January 23. According to the prospectus, Dize Pharmaceutical is a commercial-stage biopharmaceutical company, with its core therapeutic focus on oncology and hematologic diseases. During the performance period, Dize Pharmaceutical developed and commercialized Golixibate (High Ruizhe) in mainland China, a next-generation highly selective Janus kinase 1 (JAK1) inhibitor. In addition, Dize Pharmaceutical has developed, commercialized, and licensed Shuwozhe, which is the world's first approved small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of EGFR exon 20 insertion (exon20ins) mutation lung cancer.